Investigating a new way to inhibit a protein involved in brain damage from traumatic injuries and Alzheimer's disease

Development of Molecular Probe Inhibitors of Pathogenic, Cytosolic Cathespin B in Traumatic Brain Injury and Alzheimers Disease Neurodegeneration

NIH-funded research University of California, San Diego · NIH-10652388

This study is looking at how a protein called cathepsin B might cause brain damage and problems with behavior in people with traumatic brain injury and Alzheimer's disease, and the researchers want to find ways to block its harmful effects to help improve treatment options for those affected.

Quick facts

Grant typeR01 grant
Study typeNIH-funded research
Funding institutionUniversity of California, San Diego NIH-funded
Lab location1 site (La Jolla, United States)
Project IDNIH-10652388 on NIH RePORTER

What this research studies

This research focuses on understanding how a protein called cathepsin B contributes to brain damage and behavioral issues in patients with traumatic brain injury (TBI) and Alzheimer's disease (AD). The researchers aim to develop specific inhibitors that can target the harmful effects of cathepsin B in the brain without disrupting its normal functions. By using advanced molecular probes, they hope to create new therapeutic options that could improve outcomes for individuals suffering from these conditions.

Who could benefit from this research

Good fit: Ideal candidates for this research include individuals diagnosed with traumatic brain injury or Alzheimer's disease who are experiencing cognitive and behavioral deficits.

Not a fit: Patients with other forms of dementia or neurological disorders unrelated to traumatic brain injury or Alzheimer's disease may not benefit from this research.

Why it matters

Potential benefit: If successful, this research could lead to new treatments that significantly improve the quality of life for patients with traumatic brain injury and Alzheimer's disease.

How similar studies have performed: Previous research has shown promising results in targeting cathepsin B in animal models, indicating potential for success in developing similar therapeutic approaches.

Where this research is happening

La Jolla, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions Alzheimer disease dementiaAlzheimer syndromeAlzheimer's Disease
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.